Free cash flow reached $271.2M in 2026Q3 at an 18.6% margin, yet operating cash flow covered only 0.16 times reported net income and working capital swings such as -$281.7M in 2026Q1 suggest cash generation remains uneven and milestone-dependent.
Alnylam Pharmaceuticals, Inc. (ALNY) cash flow statement — 24-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 |
|---|
| Cash from Operations | 650.37M | 524.08M | -8.31M | 104.16M | -541.27M | -641.69M | -614.96M | -278.43M | -562.62M | -382.79M | -307.7M | -189.14M | -165.64M | -68.66M | -115.61M | -87.07M | -84.34M | -72.14M | 65.49M | 196.52M | -24.63M | -16.48M | -19.57M | -12.83M | -1.28M |
| Operating CF Margin % | - | 14.11% | -0.37% | 5.7% | -52.18% | -76% | -124.78% | -126.7% | -751.08% | -425.73% | -652.48% | -460.23% | -327.61% | -145.56% | -173.26% | -105.21% | -84.31% | -71.76% | 68.1% | 386.11% | -91.46% | -288.4% | -457.46% | -7288.64% | - |
| Operating CF Growth % | 386.25% | 6405.1% | -107.98% | 119.24% | 15.65% | -4.35% | -120.87% | 50.51% | -46.98% | -24.4% | -62.68% | -14.19% | -141.26% | 40.61% | -32.78% | -3.23% | -16.9% | -210.16% | -66.67% | 897.88% | -49.41% | 15.76% | -52.56% | -903.76% | - |
| Net Income | 2.72B | 313.75M | -278.16M | -440.24M | -1.13B | -852.82M | -858.28M | -886.12M | -761.5M | -490.87M | -410.11M | -290.07M | -360.39M | -89.22M | -106.01M | -57.65M | -43.52M | -47.59M | -26.25M | -85.47M | -34.61M | -42.91M | -32.65M | -25.03M | -4.14M |
| Depreciation & Amortization | 55.43M | 55.66M | 56.67M | 54.05M | 44.47M | 47.57M | 74.44M | 54.37M | 6.43M | 13.37M | 15.13M | 19.05M | 11.93M | 10.23M | 9.04M | 5.13M | 4.94M | 5.99M | 5.73M | 4.08M | 3.81M | 3.12M | 2.44M | 838K | 36K |
| Stock-Based Compensation | 307.53M | 348.24M | 272.08M | 221.68M | 230.65M | 165.72M | 139.87M | 174.84M | 157.75M | 92.82M | 75.53M | 45.78M | 33.06M | 20.7M | 12.36M | 16.8M | 19.34M | 20.17M | 18.03M | 14.47M | 8.3M | 0 | 4.11M | 0 | 0 |
| Deferred Taxes | -1.91B | -2.2M | -106.76M | 0 | 0 | -55.7M | -54.04M | -11.29M | -3.56M | 1.89M | -6.98M | 0 | -42.29M | -2.69M | -22.39M | 3.5M | 10.74M | -5.16M | -5.5M | 1.89M | -7.92M | 0 | -4.11M | 0 | 0 |
| Other Non-Cash Items | -99.19M | 253.42M | 261.94M | 257.9M | 350.32M | 216.37M | 95.75M | -12.61M | -6.84M | 2.91M | 1.51M | 984K | 221.46M | 449K | 364K | 1.08M | 3.71M | 4.86M | 9.59M | 7.12M | 8.43M | 6.55M | 7.16M | 8.46M | 172K |
| Working Capital Changes | -427.71M | -444.78M | -214.08M | 10.76M | -35.55M | -162.82M | -12.7M | 402.38M | 45.1M | -2.9M | 17.22M | 35.12M | -29.4M | -8.12M | -8.96M | -55.93M | -79.56M | -50.41M | 63.9M | 254.42M | -2.65M | 16.76M | 3.48M | 2.91M | 2.65M |
| Change in Receivables | -129.05M | -359.96M | -86.55M | -87.94M | -45.6M | -101.8M | -56.24M | -24.24M | 15.24M | -10.67M | -15.04M | 31.64M | -35.69M | -4.14M | 1.36M | 12.65M | 0 | 0 | 843K | 0 | 0 | 243K | -310K | 0 | 0 |
| Change in Inventory | -15.99M | 8.47M | 13.59M | 18.37M | -34.14M | -26.41M | -35.43M | -32.41M | -22.64M | 0 | 0 | 0 | 3.29M | 191K | -1.81M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -193.31M | 75.07M | 91.09M | 80.84M | 191.77M | 88.24M | 117.38M | 36.61M | 15.48M | -4.94M | 10.1M | 1.68M | 8.84M | 1.83M | -1.74M | -3.51M | -3.18M | 9.9M | -1.24M | -264K | 2.09M | 0 | -615K | 0 | 0 |
| Cash from Investing | -737.9M | 436.33M | -116.84M | -336.35M | 169.35M | -273.3M | -435.52M | -417.68M | 272.94M | -290.36M | 142.59M | -321.32M | -548.81M | -130.5M | 3.37M | 81.96M | 17.84M | 14.43M | 17.94M | -277.43M | -30.05M | -40.42M | -34.59M | -3.24M | -562K |
| Capital Expenditures | -149.64M | -58.7M | -34.28M | -62.21M | -72.06M | -76.37M | -70.36M | -140.16M | -126.89M | -104.21M | -64.56M | -12.95M | -8.96M | -4.01M | -8.35M | -1.29M | -4.73M | -4.95M | -10.76M | -7.79M | -4.99M | -1.95M | -9.01M | -3.12M | -562K |
| CapEx % of Revenue | 2.98% | 1.58% | 1.52% | 3.4% | 6.95% | 9.05% | 14.28% | 63.78% | 169.39% | 115.9% | 136.89% | 31.51% | 17.72% | 8.49% | 12.51% | 1.56% | 4.73% | 4.92% | 11.19% | 15.3% | 18.51% | 34.06% | 210.52% | 1772.16% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -25M | 0 | 0 | -81.96M | -17.84M | -10M | -100K | 2.34M | 0 | 40.42M | 0 | -121K | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 39.63M | 57.63M | 57.76M | -4.44M | -13.19M | -4.36M | -31.2M | 23M | -14.82M | 120M | -150M | -1.47M | 0 | 0 | -162K | 81.96M | 17.84M | 6.15M | 0 | -839K | 0 | -40.42M | 0 | 0 | 0 |
| Cash from Financing | 102.46M | -305.19M | 294.16M | 172.13M | 425.75M | 1.25B | 994.98M | 823.18M | 65.47M | 1.12B | 177.83M | 616.18M | 736.47M | 200.93M | 93.41M | 738K | 3.66M | 3.51M | 3.15M | 58.63M | 166.63M | 52.62M | 50.98M | 23.71M | 17.32M |
| Debt Issued (Net) | -55.75M | -546.95M | 0 | 0 | 254M | 500M | 200M | -30M | 0 | -120M | 150M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6.76M | -2.38M | 1.74M | 194K | 5.34M | -1.1M | 0 |
| Equity Issued (Net) | 57.17M | 250.03M | 302.95M | 147.46M | 259.36M | 246.27M | 99.5M | 781.9M | 65.47M | 1.16B | 13.71M | 585.04M | 707.04M | 172.18M | 86.44M | 738K | 993K | 3.51M | 9.91M | 61.01M | 164.89M | 52.42M | 45.31M | 27.48M | 17.34M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.47M | -257K | -596K | -378K | -15.99M | -1.39M | -359K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 101.05M | -8.27M | -8.79M | 24.67M | -87.61M | 500.85M | 695.48M | 71.28M | 0 | 83.89M | 14.13M | 31.14M | 29.42M | 28.74M | 6.97M | 0 | 2.67M | 0 | 0 | 0 | 0 | 0 | 327K | -2.67M | -28K |
| Net Change in Cash | -1.54M | 690.15M | 153.77M | -53.67M | 46.4M | 323.11M | -50.58M | 127M | -224.2M | 451.74M | 12.72M | 105.72M | 22.01M | 1.76M | -18.82M | -4.37M | -62.87M | -54.32M | 86.64M | -22.8M | 112.2M | -4.51M | -2.92M | 7.72M | 17.32M |
| Free Cash Flow | 500.73M | 465.38M | -42.59M | 41.95M | -613.33M | -718.07M | -685.32M | -418.58M | -689.5M | -487M | -372.26M | -202.09M | -174.6M | -72.66M | -123.96M | -88.36M | -89.07M | -77.09M | 54.73M | 188.73M | -29.62M | -18.43M | -28.58M | -15.95M | -1.84M |
| FCF Margin % | 9.99% | 12.53% | -1.89% | 2.29% | -59.12% | -85.05% | -139.05% | -190.48% | -920.47% | -541.64% | -789.37% | -491.74% | -345.33% | -154.05% | -185.77% | -106.77% | -89.04% | -76.69% | 56.91% | 370.81% | -109.97% | -322.46% | -667.98% | -9060.8% | - |
| FCF Growth % | 126.2% | 1192.73% | -201.54% | 106.84% | 14.59% | -4.78% | -63.72% | 39.29% | -41.58% | -30.82% | -84.2% | -15.74% | -140.29% | 41.38% | -40.29% | 0.8% | -15.54% | -240.87% | -71% | 737.26% | -60.68% | 35.5% | -79.19% | -766.68% | - |
| FCF per Share | 3.63 | 3.46 | -0.33 | 0.34 | -5.04 | -6.06 | -5.96 | -3.83 | -6.85 | -5.38 | -4.35 | -2.41 | -2.35 | -1.18 | -2.47 | -2.08 | -2.12 | -1.85 | 1.33 | 4.88 | -0.93 | -0.84 | -2.40 | -16.92 | -5.55 |
| FCF Conversion (FCF/Net Income) | 0.18x | 1.67x | 0.03x | -0.24x | 0.48x | 0.75x | 0.72x | 0.31x | 0.74x | 0.78x | 0.75x | 0.65x | 0.46x | 0.77x | 1.09x | 1.51x | 1.94x | 1.52x | -2.49x | -2.30x | 0.71x | 0.38x | 0.60x | 0.51x | 0.31x |
| Interest Paid | 250.77M | 0 | 67.58M | 0 | 0 | 0 | 0 | 172K | 775K | 2.43M | 1.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 17.45M | 0 | 14.36M | 0 | 0 | 0 | 0 | 2.57M | 1.07M | 114K | 111K | 66K | 0 | 11K | 17K | 0 | 5.77M | 5.84M | 2.67M | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ALNY stock.
Alnylam Pharmaceuticals, Inc. (ALNY) generated $524.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Alnylam Pharmaceuticals, Inc. (ALNY) generated $465.4M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Alnylam Pharmaceuticals, Inc. (ALNY) spent $58.7M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Milestone-dependent cash generation volatility
Metrics are mathematically derived from official filings.
Operating Cash Conversion Remains Erratic
According to reported quarterly figures, ALNY's operating cash flow was $341.0M in 2026Q3 against net income of $2.2B, a ratio of just 0.16 that signals most of the headline earnings are not backed by operating cash.
The gap between net income and operating cash flow is the central issue in this dataset, as the 2026Q3 net income figure is far larger than the cash generated from operations and appears to reflect non-operating or tax-related items rather than core activity. Across the ten quarters, OCF/NI ratios swing between negative and above 1.0, which suggests that earnings quality is highly sensitive to timing of collaboration receipts and working capital movements. Investors should treat reported net income as a poor proxy for underlying cash earnings until the composition of the 2026Q3 gain is clarified.
Free Cash Flow Turns Positive Unevenly
Reported free cash flow reached $271.2M in 2026Q3 at an 18.6% margin, up sharply from negative FCF in 2025Q1 and 2024Q4, indicating a genuine but inconsistent turn toward self-funding.
Free cash flow has moved from deeply negative readings in early 2025 to several strong positive quarters, with 2025Q3 at $313.0M and 2026Q3 at $271.2M, which reflects the commercial ramp of the TTR franchise. However, quarterly FCF margins range from roughly -21% to 25%, so the trajectory is more a series of step changes than a steady compounding trend. The durability of these inflows depends on whether product-driven operating cash can carry the business without reliance on lumpy partner payments.
Working Capital Swings Drive Quarterly Noise
Working capital changes were -$103.2M in 2026Q3 and -$281.7M in 2026Q1 according to reported cash flow figures, large enough to materially distort quarterly operating cash flow.
The magnitude of working capital movements relative to operating cash flow indicates that receivable timing and collaboration-related balances are a meaningful driver of reported OCF. A large outflow in 2026Q1 followed by a partial reversal implies that cash conversion is sensitive to billing cycles rather than purely to demand. Analysts should monitor whether receivable and inventory balances normalize, since persistent build-ups would suggest weaker collection efficiency than headline revenue growth implies.
Capital Intensity Remains Light Relative to Revenue
Based on reported figures, CapEx ran at only 0.8% to 2.7% of revenue across recent quarters, with 2026Q2 at $34.7M, consistent with an asset-light, outsourced-manufacturing-heavy model.
Low capital intensity means that the bulk of cash generation is available for pipeline funding and debt service rather than plant maintenance. D&A broadly tracks CapEx at roughly $13M to $14M per quarter, suggesting that maintenance reinvestment is modest and that growth capex has not yet become a major claim on cash. This structure supports margin flexibility, though it also means the company relies on third parties for manufacturing capacity.
Stock Compensation Masks True Cash Burden
As reported in financial statements, stock-based compensation ran between $56.7M and $111.7M per quarter, a non-cash add-back that flatters operating cash flow relative to the economic cost of employee pay.
Because SBC is excluded from operating cash outflows, the reported OCF partially reflects a cost that is settled in equity rather than cash, which may overstate the cash economics available to shareholders. The recurring size of this charge suggests that management compensation is a material component of the cost base, and dilution from it may offset part of the apparent cash improvement. Investors should evaluate free cash flow after accounting for SBC when assessing true owner earnings.